Progressive Corp/ US7433151039 /
7/26/2024 9:59:53 PM | Chg. +2.95 | Volume | Bid10:25:00 PM | Ask10:25:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
215.78USD | +1.39% | 54,117 Turnover: 6.42 mill. |
-Bid Size: - | -Ask Size: - | 126.32 bill.USD | 0.19% | 32.63 |
GlobeNewswire
6/25
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
6/24
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Tri...
GlobeNewswire
6/24
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geo...
GlobeNewswire
6/24
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-4...
GlobeNewswire
6/13
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Progr...
GlobeNewswire
6/12
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo...
GlobeNewswire
6/12
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japa...
GlobeNewswire
6/11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
6/11
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b...
GlobeNewswire
6/11
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclero...
GlobeNewswire
6/10
LifeWallet’s Proprietary Data System is Instrumental in Class Certification Against USAA Property an...